2026-10-14T07:00:38Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34034737 2026-09-30T17:27:28Z category_7 category_12 category_21 category_61 category_64 category_106 category_128 portal_5 item_type_1 month_year_09_2026

<p>PRISMA-ScR flow diagram of study selection.</p> Mahmood Ahmadi-hamedani (14233961) Kimia Satari (25145086) Medicine Cell Biology Biotechnology Developmental Biology Cancer Science Policy Hematology megakaryocyte cytology ); marked methodological heterogeneity frequently necessitates sedation xlink "> following xlink "> aim standard data sheet related platelet production assessing megakaryocytic activity immature platelet fraction one study used 35 records identified xlink "> evidence full systematic review reticulated platelet parameters marrow reference standard classify primary studies xlink "> platelet status systematic review related immature reference criteria feline data reticulated platelets thrombopoietic activity marrow activity evidence generated evidence across scoping review small number scr guidelines scoping reviews remainder relied potential indicators marrow marker informative synthesis findings etc expensive procedure exhaustive search essentially limited ensure eligibility eligibility criteria currently feasible comprehensive assessment clinical information cab abstracts <div> <p>Background</p><p>Evaluating bone marrow is an invasive and expensive procedure that frequently necessitates sedation or anesthesia in dogs and cats. The immature platelet fraction (IPF(and related immature or reticulated platelet parameters, has been suggested as a non-invasive alternative for assessing megakaryocytic activity. However, a comprehensive assessment of the depth and balance of evidence across the two most prevalent companion animal species has not been conducted previously.</p> <p>Objective</p><p>Aim of this scoping review was: (1) to map and classify primary studies that report on IPF or reticulated platelets in the context of thrombopoietic activity or bone-marrow activity in dogs and/or cats, (2) to classify the subjects, assays, reference criteria, clinical information, findings etc; and (3) to highlight principal evidence gaps and identify if the evidence generated is adequate and comparable for the systematic review or for a future meta-analysis.</p> <p>Methods</p><p>Following the Population-Concept-Context (PCC) framework and the PRISMA Extension for Scoping Reviews (PRISMA-ScR guidelines, an exhaustive search was conducted in PubMed/MEDLINE, Web of Science, Scopus, and CAB Abstracts. The parameters of immature and reticulated platelets have been examined in relation to bone marrow and platelet status. Records were reviewed to ensure eligibility, and a standard data sheet was used to extract data.</p> <p>Results</p><p>Of 35 records identified, 10 met the eligibility criteria. Nine of the ten included studies reported data only in dogs; a single retrospective study reported data in both dogs and cats, and no study addressed cats exclusively. Only one study used a direct bone-marrow reference standard (megakaryocyte cytology); the remainder relied on indirect or clinical classification.</p> <p>Conclusions</p><p>Evidence for IPF/reticulated platelets as a bone-marrow marker is considerably more developed in dogs than in cats. Feline data are essentially limited to a single retrospective analyzer study. Given the small number of studies and marked methodological heterogeneity, a full systematic review with meta-analysis is not currently feasible; a scoping review is the appropriate and informative synthesis at this stage.</p></div> 2026-09-30T17:27:24Z Image Figure 10.1371/journal.pone.0358333.g001 https://figshare.com/articles/figure/_p_PRISMA-ScR_flow_diagram_of_study_selection_p_/34034737 CC BY 4.0